• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Application o Market segments o Comparison by Application o Hepatitis - Market size and forecast 2019-2024 o HIV - Market size and forecast 2019-2024 o Herpes - Market size and forecast 2019-2024 o Influenza - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Application • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Market challenges o Market trends • Vendor Landscape o Overview o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Bristol-Myers Squibb Co. o F. Hoffmann-La Roche Ltd. o Gilead Sciences Inc. o GlaxoSmithKline Plc o Johnson & Johnson o Merck & Co. Inc. o Novartis AG o Pfizer Inc. o Sanofi • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 5 • 5.Key Finding 6 • 6.Key Finding 7 • 7.Key Finding 8 • 8.Parent market • 9.Market characteristics • 10.Offerings of vendors included in the market definition • 11.Market segments • 12.Global - Market size and forecast 2019 - 2024 ($ billion) • 13.Global market: Year-over-year growth 2019 - 2024 (%) • 14.Five forces analysis 2019 & 2024 • 15.Bargaining power of buyers • 16.Bargaining power of suppliers • 17.Threat of new entrants • 18.Threat of substitutes • 19.Threat of rivalry • 20.Market condition - Five forces 2019 • 21.Application - Market share 2019-2024 (%) • 22.Comparison by Application • 23.Hepatitis - Market size and forecast 2019-2024 ($ billion) • 24.Hepatitis - Year-over-year growth 2019-2024 (%) • 25.HIV - Market size and forecast 2019-2024 ($ billion) • 26.HIV - Year-over-year growth 2019-2024 (%) • 27.Herpes - Market size and forecast 2019-2024 ($ billion) • 28.Herpes - Year-over-year growth 2019-2024 (%) • 29.Influenza - Market size and forecast 2019-2024 ($ billion) • 30.Influenza - Year-over-year growth 2019-2024 (%) • 31.Others - Market size and forecast 2019-2024 ($ billion) • 32.Others - Year-over-year growth 2019-2024 (%) • 33. Market opportunity by Application • 34.Customer landscape • 35.Market share by geography 2019-2024 (%) • 36.Geographic comparison • 37.North America - Market size and forecast 2019-2024 ($ billion) • 38.North America - Year-over-year growth 2019-2024 (%) • 39.Europe - Market size and forecast 2019-2024 ($ billion) • 40.Europe - Year-over-year growth 2019-2024 (%) • 41.Asia - Market size and forecast 2019-2024 ($ billion) • 42.Asia - Year-over-year growth 2019-2024 (%) • 43.ROW - Market size and forecast 2019-2024 ($ billion) • 44.ROW - Year-over-year growth 2019-2024 (%) • 45.Key leading countries • 46.Market opportunity by geography ($ billion) • 47.Impact of drivers and challenges • 48.Vendor landscape • 49.Landscape disruption • 50.Industry risks • 51.Vendors covered • 52.Market positioning of vendors • 53.AbbVie Inc. - Overview • 54.AbbVie Inc. - Business segments • 55.AbbVie Inc. - Key offerings • 56.AbbVie Inc. - Key customers • 57.AbbVie Inc. - Segment focus • 58.Bristol-Myers Squibb Co. - Overview • 59.Bristol-Myers Squibb Co. - Product and service • 60.Bristol-Myers Squibb Co. - Key offerings • 61.Bristol-Myers Squibb Co. - Key customers • 62.Bristol-Myers Squibb Co. - Segment focus • 63.F. Hoffmann-La Roche Ltd. - Overview • 64.F. Hoffmann-La Roche Ltd. - Business segments • 65.F. Hoffmann-La Roche Ltd. - Key offerings • 66.F. Hoffmann-La Roche Ltd. - Key customers • 67.F. Hoffmann-La Roche Ltd. - Segment focus • 68.Gilead Sciences Inc. - Overview • 69.Gilead Sciences Inc. - Business segments • 70.Gilead Sciences Inc. - Key offerings • 71.Gilead Sciences Inc. - Key customers • 72.Gilead Sciences Inc. - Segment focus • 73.GlaxoSmithKline Plc - Overview • 74.GlaxoSmithKline Plc - Business segments • 75.GlaxoSmithKline Plc - Key offerings • 76.GlaxoSmithKline Plc - Key customers • 77.GlaxoSmithKline Plc - Segment focus • 78.Johnson & Johnson - Overview • 79.Johnson & Johnson - Business segments • 80.Johnson & Johnson - Key offerings • 81.Johnson & Johnson - Key customers • 82.Johnson & Johnson - Segment focus • 83.Merck & Co. Inc. - Overview • 84.Merck & Co. Inc. - Business segments • 85.Merck & Co. Inc. - Key offerings • 86.Merck & Co. Inc. - Key customers • 87.Merck & Co. Inc. - Segment focus • 88.Novartis AG - Overview • 89.Novartis AG - Business segments • 90.Novartis AG - Key offerings • 91.Novartis AG - Key customers • 92.Novartis AG - Segment focus • 93.Pfizer Inc. - Overview • 94.Pfizer Inc. - Business segments • 95.Pfizer Inc. - Key offerings • 96.Pfizer Inc. - Key customers • 97.Pfizer Inc. - Segment focus • 98.Sanofi - Overview • 99.Sanofi - Business segments • 100.Sanofi - Key offerings • 101.Sanofi - Key customers • 102.Sanofi - Segment focus • 103.Currency conversion rates for US$ • 104.Research Methodology • 105.Research Methodology • 106.Validation techniques employed for market sizing • 107.Information sources • 108.List of abbreviations

AbbVie Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi